Get the Stockscreener App
3.53
4.85%
-0.18
After Hours:
3.53
Alvotech stock is traded at $3.53, with a volume of 274.83K.
It is down -4.85% in the last 24 hours and up +1.73% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$3.71
Open:
$3.71
24h Volume:
274.83K
Relative Volume:
0.53
Market Cap:
$1.10B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
36.62
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
+4.13%
1M Performance:
+1.73%
6M Performance:
-58.47%
1Y Performance:
-58.62%
1-Day Range:
$3.51
$3.78
1-Week Range:
$3.42
$3.78
52-Week Range:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.53 | 1.13B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Cash per share of Alvotech – DUS:Z45 - TradingView — Track All Markets
ALVO SEC FilingsAlvotech 10-K, 10-Q, 8-K Forms - Stock Titan
ALVO Technical Analysis & Stock Price Forecast - Intellectia AI
Alvotech: Improving Fundamentals Signal Potential Bottom For This Biosimilar Player (ALVO) - Seeking Alpha
Retail Trends: Whats the outlook for Alvotech Equity Warrants sector2026 Snapshot & Safe Entry Trade Reports - baoquankhu1.vn
Alvotech’s Price Rises But Technical Signals Turn Bearish - Bitget
Performance Recap: Is Alvotech a top pick in the sector2026 Trade Ideas & Long-Term Growth Plans - baoquankhu1.vn
Why Is Alvotech (ALVOW) Stock Down Today? - Meyka
Alvotech stock: Biosimilar innovator with global growth potential - AD HOC NEWS
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Alvotech (NASDAQ:ALVO) Stock Price Down 9.5%Here's What Happened - MarketBeat
Alvotech Plummets 9.5% Amid Market Volatility and Sector Uncertainty - Bitget
Alvotech CCO Anil Okay steps down to become Adalvo CEO - MSN
Published on: 2026-04-07 05:57:03 - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Trading Up 7.2%Here's What Happened - MarketBeat
ETFs Investing in Alvotech Stocks - TradingView
Institution Moves: Is Alvotech stock overvalued or fairly pricedMarket Movers & Weekly High Return Forecasts - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Stock Rating Lowered by Wall Street Zen - MarketBeat
ALVO Should I Buy - Intellectia AI
ALVO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag - MSN
Alvotech (ALVO) revenue surges 21% year-over-year in 2025 - MSN
ALVO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alvotech Earnings Call: Growth Momentum Meets FDA Risk - The Globe and Mail
Alvotech (ALVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025 - Insider Monkey
Does Alvotech’s (ALVO) Reaffirmed 2026 Revenue Target Redefine Its Biosimilar Strategy Narrative? - Sahm
Alvotech’s comprehensive biosimilars platform presents an uneven risk-reward profile as the market factors in the FDA approval challenge - Bitget
Alvotech : Transactions of Managers and Closely Associated Persons - marketscreener.com
Alvotech : Managers’ transactionsManager Transaction NotificationATP ehf.EN - marketscreener.com
Alvotech : Managers' transactionsALVOTECH - MarketScreener
Alvotech Files Annual Report 2025 with the U.S. SEC - Quiver Quantitative
Alvotech Files Annual Report with the SEC - The Manila Times
Alvotech files Annual Report with the SEC - GlobeNewswire
Alvotech Publishes 2025 Annual Report - GlobeNewswire
Alvotech (NASDAQ: ALVO) turns 2025 profit while managing heavy debt and FDA CRLs - Stock Titan
Alvotech (NASDAQ:ALVO) Shares Up 5.3%Time to Buy? - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Drops By 17.0% - MarketBeat
Alvotech Stock: Biosimilar Innovator Positions for U.S. Market Expansion Amid Global Growth Push - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Alvotech Faces Weak Start with 6.54% Gap Down Amid Market Concerns - Markets Mojo
Retail Trends: What is the dividend yield of Alvotech Equity WarrantMarket Rally & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Fed Meeting: Whats the fair value of Alvotech stock2026 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position - Yahoo Finance
Alvotech Shares Plunge to New 52-Week Low at $3.03 - Markets Mojo
Alvotech stock hits new 52-week low on UBS price target cut to $6 amid biosimilar launch delays - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Alvotech price target lowered to $4 from $5 at Barclays - TipRanks
Alvotech Drops 14% Amid Prevailing Negative Market Sentiment - Bitget
Alvotech price target lowered to $4 from $8 at Deutsche Bank - TipRanks
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):